Last reviewed · How we verify
NCT04944966: MALHERBAL
Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria
Phase 2 trial testing Maytenus Senegalensis in Malaria in 12 participants. Completed in 25 September 2022.
25 September 2022
Quick facts
| Lead sponsor | Ifakara Health Institute |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 2 June 2021 |
| Primary completion | 25 September 2022 |
| Estimated completion | 25 September 2022 |
| Sites | 1 location across Tanzania |
Drugs / interventions tested
- Maytenus Senegalensis — full drug profile →
Conditions studied
- Malaria — all drugs for Malaria →
Sponsor
Ifakara Health Institute
Who can join
Adults 18 to 45, male only, with Malaria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Antimalarial Herbal medicine known as Maytenus senegalensis will be evaluated for its safety, tolerability and efficacy among Tanzanian male adults aged 18 to 45 years. The first primary objective is to assess the safety and tolerability of malaria herbal remedy of Maytenus senegalensis among healthy male adults aged 18 to 45 years in Tanzania. And the second objective is to evaluate the safety, tolerability as well as efficacy of malaria herbal remedy Maytenus senegalensis (MALHERBAL) for the treatment of Tanzanian adults aged 18 to 45 years with uncomplicated malaria compared to Artemether-lumefantrine.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The effect of an anti-malarial herbal remedy, Maytenus senegalensis, on electrocardiograms of healthy Tanzanian volunteers.
Kassimu KR, Ali AM, Omolo JJ, Mdemu A, et al · · 2024 · cited 3× · PMID 38609987 · DOI 10.1186/s12936-024-04935-w -
Safety and Tolerability of an Antimalarial Herbal Remedy in Healthy Volunteers: An Open-Label, Single-Arm, Dose-Escalation Study on <i>Maytenus senegalensis</i> in Tanzania.
Kassimu K, Milando F, Omolo J, Mdemu A, et al · · 2022 · cited 3× · PMID 36548651 · DOI 10.3390/tropicalmed7120396 -
Motivations and barriers for healthy participants to participate in herbal remedy clinical trial in Tanzania: A qualitative study based on the theory of planned behaviour.
Kassimu KR, Milando FA, Omolo JJ, Nyaulingo G, et al · · 2022 · cited 2× · PMID 35862395 · DOI 10.1371/journal.pone.0271828
Verify or expand the search:
- PubMed search for NCT04944966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malaria
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
- NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
- NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting
Other Ifakara Health Institute trials
Trials by the same sponsor.
- NCT06172686 — In-vivo Transmission Model in Semi-immune Adults · Phase 1 · unknown
- NCT05125133 — Evaluation of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Tanzania. · NA · unknown
- NCT01930331 — Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04944966 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ifakara Health Institute
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04944966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing